1. Home
  2. CATX
  3. Earnings

AI Earnings Predictions for Perspective Therapeutics Inc. (CATX)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

BUY

1-Day Prediction

+5.81%

$0.92

100% positive prob.

5-Day Prediction

+11.59%

$0.97

100% positive prob.

20-Day Prediction

+21.43%

$1.05

95% positive prob.

Price at prediction: $0.87 Confidence: 99.8% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 BUY +5.81% +11.59% +21.43% 99.8% Pending
Q2 2026 SELL -10.99% -18.79% -17.17% 100.0% +7.33%
Q1 2026 SELL -11.81% -20.37% -16.62% 100.0% -3.09%
Q4 2025 SELL -15.28% -25.42% -20.03% 100.0% -4.16%

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K BUY

Nov 9, 2026 · 100% conf.

AI Prediction BUY

1D

+5.81%

$0.92

Act: -7.67%

5D

+11.59%

$0.97

20D

+21.43%

$1.05

Price: $0.87 Prob +5D: 100% AUC: 1.000
0001193125-26-453708

EX-99.1

2 catx-ex99_1.htm

EX-99.1

EX-99.1

Perspective Therapeutics Provides Recent Business Highlights and

Reports 3Q 2026 Results

• Updated interim data from the Phase 1/2a bamzireotide navoxetan (VMT-α-NET) presentations continue to support an emerging therapeutic window and potential to achieve a best-in-class profile in NETs

• Meaningful antitumor activity observed for lapemelanotide zapixetar (VMT01) monotherapy in metastatic melanoma to be evaluated with additional patients

• PSV359 received Fast Track Designation from the FDA for FAP-positive solitary fibrous tumors; agreement in place with Merck to support potential evaluation in combination with Keytruda® (pembrolizumab) for certain types of lung and colorectal cancers

• Approximately $202 million in cash, cash equivalents, and short-term investments as of September 30, 2026; expected to be sufficient to fund current planned clinical milestones and operational investments into 2028

SEATTLE – November 9, 2026 – Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced systemic treatments for cancers, today provided a business update and announced results for the quarter ended September 30, 2026.

“We have presented clinical data that demonstrated the potential of delivering alpha radiation via our proprietary targeted oncology platform,” said Thijs Spoor, Perspective’s Chief Executive Officer. “With encouraging clinical findings observed to date that further support the best‑in‑class potential of bamzireotide, continued progress across two additional programs targeting melanoma and FAP-α-positive solid tumors, and investments in our manufacturing capabilities, we are well-positioned to lead the development of the field.”

Recent Program Updates

Bamzireotide navoxetan (VMT-α-NET) in SSTR2-positive neuroendocrine tumors (NETs) and meningioma

• Updated data were presented at the European Society for Medical Oncology (ESMO) Congress 2026 and the 2026 North American Neuroendocrine Tumors Society (NANETS) Multidisciplinary NET Medical Symposium showing strong clinical efficacy data. Read our complete NANETS press release here, and view our NANETS presentation on the Company’s website.

• Enrollment in Cohort 4 has been completed. As of October 30, 2026, Cohort 4 of the dose‑finding study for NETS closed for recruitment with 20 patients enrolled. The meningioma cohort remains open for recruitment with two patients treated as of October 30, 2026.

• Pre-Phase 3 activities are progressing. We are targeting an end-of-Phase 2 meeting with the FDA in 1Q 2027.

• European orphan medicinal product designation granted in July 2026 for the treatment of gastroenteropancreatic (GEP)-NETs.

Lapemelanotide zapixetar (VMT01) in MC1R-positive melanoma:

• Data with longer follow-up were presented at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting showing strong, durable disease control in heavily pre‑treated patients. Read our complete SITC press release here, and view our SITC poster on the Company’s website.

• Recruiting more patients to corroborate encouraging monotherapy findings. As of October 30, 2026, 12 patients have been treated in a monotherapy cohort allowing up to a cumulative 9 mCi (333 MBq), administered in three treatments of 3.0 mCi every eight weeks. Five patients have been treated since the cohort reopened during 3Q 2026; by mid-2027, they are expected to reach at least 24 weeks of follow-up. This cohort remains open for enrollment.

PSV359 in FAP-α-positive solid tumors

• Study progressing. This dose-finding study progressed into the third dose cohort, with a cumulative dose of 24 mCi administered in up to four treatments every eight weeks during 2Q 2026; as of September 30, 2026, 17 patients had been treated across the three cohorts. The next clinical update is planned in 2027.

• Fast Track designation granted. In October 2026, the FDA granted PSV359 Fast Track Designation for adult patients with locally advanced unresectable and/or metastatic fibroblast activation protein (FAP)-positive solitary fibrous tumors. In September 2026, we entered into a clinical trial collaboration and supply agreement with Merck to support potential evaluation of PSV359 in combination with Keytruda® (pembrolizumab) for certain types of lung and colorectal cancers.

Manufacturing: We expect construction to be completed at the Chicago metro site in early 2027.

Third Quarter 2026 Financial Summary

Cash, cash equivalents, and short-term investments as of September 30, 2026, were approximately $202 million as compared to approximately $145 million as of December 31, 2025. We believe our cash, cash equivalents, and short-term investments are sufficient to fund our current planned clinical milestones and operational investments into 2028.

• Research and development expenses were $26.1 million for the three months ended September 30, 2

2026
Q2

Q2 2026 Earnings

8-K SELL

Aug 10, 2026 · 100% conf.

AI Prediction SELL

1D

-10.99%

$2.67

Act: +6.00%

5D

-18.79%

$2.44

Act: +7.33%

20D

-17.17%

$2.48

Price: $3.00 Prob +5D: 0% AUC: 1.000
0001193125-26-342495

EX-99.1

2 catx-ex99_1.htm

EX-99.1

EX-99.1

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results

• Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 subject to regulatory feedback; sufficient isotope access and manufacturing capacity

• VMT-α-NET study update accepted for oral presentation at ESMO 2026

• VMT01 melanoma and PSV359 FAP-α clinical programs continue to advance

• Approximately $237 million in cash, cash equivalents, and short-term investments as of June 30, 2026; expected to be sufficient to fund current planned clinical milestones and operational investments into late 2027

SEATTLE – August 10, 2026 – Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended June 30, 2026.

“The team at Perspective is highly energized as we continue to build on the significant clinical progress we're making across our pipeline, prepare for our first Phase 3 study, and advance our flagship Chicago manufacturing facility toward completion,” said Thijs Spoor, Perspective's CEO. “As precision oncology continues to evolve, long-term leadership will require differentiated science, integrated manufacturing, and the ability to reliably deliver these therapies at commercial scale. We are continuing to bring the platform that delivers.”

Recent Program Updates

We advanced our four-program 212Pb pipeline, expanded our manufacturing network and attracted strong leadership.

• Bamzireotide navoxetan (VMT-α-NET) in SSTR2-positive neuroendocrine tumors (NETs) and meningioma: 76 NETs patients across four cohorts and one meningioma patient treated as of July 31. ASCO 2026 interim data were consistent with prior findings and showed continued deepening of response. Updated data on NETs patients will be presented at ESMO on October 23. By late 2026, all 46 Cohort 2 patients will have had the opportunity for at least 60 weeks of follow-up, which is expected to inform the Phase 3 study design.

Preparing for a Phase 3 study evaluating a proposed cumulative 20 mCi (740 MBq) dose administered in up to four treatments every eight weeks. Additional dose cohorts could provide optionality and opportunity to further define VMT-α-NET’s therapeutic window. Phase 3 site activation targeted around year-end 2026, subject to regulatory feedback and protocol finalization.

• Lapemelanotide zapixetar (VMT01) in MC1R-positive melanoma: 27 patients enrolled across multiple dose cohorts either as monotherapy or in combination with the immune checkpoint inhibitor nivolumab as of July 31. We are focused on a cumulative 9 mCi (333 MBq) dose administered in up to three treatments every eight weeks. Seven patients received this treatment regimen as a monotherapy, and six patients received this dose in combination with nivolumab.

Data presented at ASCO 2026 showed two partial responses among seven patients treated with 3.0 mCi monotherapy; safety data from 27 patients showed treatment was generally well tolerated. Six nivolumab combination patients are expected to reach at least 24 weeks of follow-up by late 2026.

• PSV359 in FAP-α-positive solid tumors: 17 patients treated across three dose cohorts as of July 31. Cohort 3 opened and closed during 2Q 2026. The next clinical update is planned in 2027.

• PSV594 in CCK2R-positive solid tumors: Preclinical data and first-in-human biodistribution observations support continued pre-IND development of PSV594.

Manufacturing: We expect the Chicago metro site to complete construction in early 2027, followed by the Los Angeles metro site in 2H 2027, expanding the network to four regional sites by the end of 2027. We believe we have sufficient capacity and isotope access to support ongoing studies and the planned VMT-α-NET Phase 3 study.

Corporate update: In July 2026, we announced that Paul Lyne, Ph.D. was appointed as Chief Science Officer.

Second Quarter 2026 Financial Summary

Cash, cash equivalents, and short-term investments as of June 30, 2026, were approximately $237 million as compared to approximately $145 million as of December 31, 2025. We believe our cash, cash equivalents, and short-term investments are sufficient to fund our current planned clinical milestones and operational investments into late 2027.

• Research and development expenses were $21.5 million for the three months ended June 30, 2026, compared to $16.6 million for the three months ended June 30, 2025.

• General and administrative expenses were $7.8 million for the three months ended June 30, 2026, compared to $7.7 million for the three months ended June 30, 2025.

• Net loss for the three months ended June 30, 2026, was $26.8

2026
Q1

Q1 2026 Earnings

8-K SELL

May 11, 2026 · 100% conf.

AI Prediction SELL

1D

-11.81%

$3.42

Act: -2.84%

5D

-20.37%

$3.09

Act: -3.09%

20D

-16.62%

$3.24

Act: -22.68%

Price: $3.88 Prob +5D: 0% AUC: 1.000
0001193125-26-216777

EX-99.1

2 catx-ex99_1.htm

EX-99.1

EX-99.1

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results

• Differentiated ²¹²Pb radiopharmaceutical platform designed to optimize tumor killing, safety, patient convenience and supply scalability

• Three clinical-stage oncology programs advancing across neuroendocrine tumors, melanoma and FAP-positive solid tumors with multiple clinical catalysts expected in 2026 across VMT-α-NET, VMT01 and PSV359 programs; lead program, VMT-α-NET, advancing toward a registration‑enabling study

• Regional manufacturing network designed to support reliable supply of ready-to-administer radiopharmaceuticals for clinical development and potential commercialization; Chicago site expected to complete construction in 2026

• Cash runway expected into late 2027 to support planned clinical milestones and operational investments; cash, cash equivalents, and short-term investments of approximately $271M as of March 31, 2026

SEATTLE – May 11, 2026 – Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended March 31, 2026.

“The first quarter of 2026 was marked by continued execution across our clinical programs and strengthening of our financial position,” said Thijs Spoor, Perspective’s CEO. “Our focus on engineering the alpha advantage across every part of the radiopharmaceutical value chain - from the radioisotope to optimized structural chemistry, theranostic processes, and regional manufacturing - differentiates Perspective, and we look forward to providing clinical and manufacturing updates throughout 2026.”

Clinical Highlights

VMT-α-NET

We are conducting a multi-center, open-label, dose-finding study (clinicaltrials.gov identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapies (RPT).

• Updated interim data from the study, as of a data cut-off (DCO) date of March 4, 2026, were presented at the American Association for Cancer Research Annual Meeting 2026 in April 2026.

• As of April 30, 2026, the first 23 patients in Cohort 2 have had the opportunity for at least 60 weeks of follow-up since beginning treatment. By late 2026, all 46 patients in Cohort 2 will have had the opportunity for at least 60 weeks of follow-up since beginning treatment.

• We believe our clinical data package positions us for meaningful regulatory engagement in 2026 to align on the path forward.

• As of April 30, 2026, a total of 20 patients have been treated in Cohort 3. This cohort is now closed to enrollment. By late 2026, the eight patients initially enrolled for dose-limiting toxicity (DLT) assessment will have had the opportunity for at least 48 weeks of follow-up since beginning treatment.

• Cohort 4 is now open for recruitment.

• During the dose-finding phase of the study, we enrolled primarily NET patients whose disease originated in the pancreas or the digestive tract. We have an allowance for enrollment of NET patients whose disease originated in the lung (of which small cell lung cancer is a subset), pheochromocytoma/paraganglioma NETs, and SSTR2+ meningioma.

• We opened a proof-of-concept cohort of meningioma patients. To date, there is no approved systematic therapy for this disease. The unmet medical need may support an expedited development path.

VMT01

VMT01 is an MC1R-targeted RPT that can be radiolabeled with either 203Pb for patient selection and dosimetry assessment or 212Pb for alpha-particle therapy. We are conducting a multi-center, open-label, dose-finding study (clinicaltrials.gov identifier NCT05655312) in heavily pre-treated patients with histologically confirmed melanoma and MC1R-positive imaging scans.

• Since dosing re-opened for 3.0 mCi of VMT01 as monotherapy, and was initiated for 3.0 mCi of VMT01 in combination with nivolumab in September 2025, 10 patients had received VMT01 3.0 mCi treatment as of February 28, 2026; six patients had received VMT01 at 3.0 mCi in combination with nivolumab, and four patients had received 3.0 mCi of VMT01 as monotherapy, in addition to the three patients who received this monotherapy dose in late 2023. Both cohorts are now closed for enrollment.

• By late 2026, the 10 patients who had received VMT01 3.0 mCi treatment since the initiation or re-opening of these cohorts in September 2025 will have had the opportunity for at least 24 weeks of follow-up after their initial doses, sufficient time to have completed at least one scan after the full course of treatment (up to three doses every eight weeks).

PSV359

We designed PSV359 to target and deliver 212Pb to tumor sites expressing fibroblast activation protein-α (

About Perspective Therapeutics Inc. (CATX) Earnings

This page provides Perspective Therapeutics Inc. (CATX) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on CATX's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: